Excel Industries Ltd

- The transcript does not mention any current or future fundraising plans through debt or equity. - There is no discussion on issuing new shares, raising capital, or taking on debt during the call. - The company focuses on internal funding for its CAPEX plans (₹200-300 crores over 3 years) from operational cash flows. - They have confirmed a trade advance of ₹25 crores from a customer related to a contract manufacturing project, but this is not a fundraising activity. - Overall, no explicit indication of raising funds via debt or equity at present or in near future was provided.

- Excel Industries plans total CAPEX of Rs 200-300 crores over the next three years, covering both maintenance and growth. - Recently signed a long-term 5-year contract manufacturing deal requiring Rs 40 crores investment for a dedicated production line, commissioning expected by June 2026. - Commissioned a capacity expansion for a key biocide product in October 2025 with Rs 10.33 crores invested; full-year revenue expected at Rs 15 crores. - Ongoing debottlenecking and modernization CAPEX of around Rs 35-40 crores excluding raw materials, staggered over 12-18 months, covering multiple projects. - New R&D center becoming operational in Q3 FY26 to support innovation and growth initiatives. - Strategic investments focus on expanding specialty chemicals, contract manufacturing, and reducing agrochemical sector dependence.

- Current capacity utilization is 70% to 75%, with effective maximum utilization around 85% to 90% due to operational flexibility and maintenance. - Existing assets offer headroom for volume growth without immediate need for major expansion. - New CAPEX of approximately Rs 200-300 crores planned over next 3 years, including Rs 35-40 crores for a long-term specialty chemical contract manufacturing project expected to generate Rs 35-40 crores in annual revenue. - Incremental revenue expected from newly commissioned biocide capacity (~Rs 15 crores annual revenue) and other contract manufacturing projects (~Rs 10-12 crores), with combined potential incremental revenue around Rs 60 crore at peak. - Business growth focused on performance solutions segment and contract manufacturing to de-risk agrochemical dependency. - Full year FY26 top line growth influenced by subdued agrochemical demand due to extended monsoon; expectation of normalization and potential revival in Q4 or beyond. - No specific peak revenue guidance given, due to dynamic pricing and market conditions.

- Excel Industries targets full-year EBITDA margins of 13% to 15% for FY26, reflecting stable profitability despite Q3 being a lean quarter. - Incremental revenue growth is anticipated from contract manufacturing and specialty chemicals, with new long-term contracts expected to generate combined peak revenues of around ₹60 crores by FY27/FY28. - The new R&D center, operational in Q3 FY26, is aimed at strengthening product pipeline and innovation, contributing to medium to long-term growth. - Capacity utilization currently at 70-75%, with headroom to increase up to 85-90%, indicating potential for volume growth without immediate large-capacity expansion. - Strategic investments in R&D and sustainability are expected to support long-term growth and profitability. - Despite near-term demand softness due to agrochemical sector disruptions, normalization is expected by Q4 FY26 or later. - Overall, management remains optimistic about long-term earnings growth driven by performance solutions and contract manufacturing diversification.

The transcript does not explicitly mention the current or expected order book or pending orders for Excel Industries Limited. However, some relevant points related to contracts and future business are: - Signed a binding term sheet for a long-term contract manufacturing arrangement spanning five years with a specialty chemicals company. - New dedicated production line associated with this contract expected to be commissioned by June 2026. - Estimated investment for this project is Rs 40 crores, with expected annual revenue of Rs 35-40 crores (excluding raw materials), EBITDA accretive. - Recently commissioned capacity expansion for a key biocide product; initial supplies under a long-term supply contract have commenced. - R&D center to become operational in Q3 FY26, underscoring focus on developing new products and technologies. - Actively exploring new contract manufacturing opportunities and product pipeline to reduce dependence on agrochemical revenues.